Abstract
Pathophysiological mechanisms of neurological disorders in patients with coronavirus disease 2019 (COVID-19) are poorly understood, partly because of a lack of high-resolution neuroimaging data. We applied SynthSR, a convolutional neural network that synthesizes high-resolution isotropic research-quality data from thick-slice clinical MRI data, to a cohort of 11 patients with severe COVID-19. SynthSR successfully synthesized T1-weighted MPRAGE data at 1 mm spatial resolution for all 11 patients, each of whom had at least one brain lesion. Correlations between volumetric measures derived from synthesized and acquired MPRAGE data were strong for the cortical grey matter, subcortical grey matter, brainstem, hippocampus, and hemispheric white matter (r=0.84 to 0.96, p≤0.001), but absent for the cerebellar white matter and corpus callosum (r=0.04 to 0.17, p>0.61). SynthSR creates an opportunity to quantitatively study clinical MRI scans and elucidate the pathophysiology of neurological disorders in patients with COVID-19, including those with focal lesions.
Competing Interest Statement
Conflicts of interests: BF has a financial interest in CorticoMetrics, a company whose medical pursuits focus on brain imaging and measurement technologies. BF's interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies.
Funding Statement
This study was supported by the James S. McDonnell Foundation COVID-19 Recovery of Consciousness Consortium, the NIH Directors Office (DP2HD101400), the NIH National Institute of Neurological Disorders and Stroke (R21NS109627, R25NS06574309, R01NS0525851, R21NS072652, R01NS070963, R01NS083534, U01NS086625, U24NS10059103, R01NS105820), NIH National Institute on Aging (R01AG070988, R56AG064027, R01AG064027, R01AG008122, R01AG016495), NIH National Institute for Biomedical Imaging and Bioengineering (P41EB015896, R01EB023281, R01EB006758, R21EB018907, R01EB019956, P41EB030006), NIH National Institute of Mental Health (R01MH123195, R01MH121885, RF1MH123195), NIH BRAIN Initiative (RF1MH123195), BRAIN Initiative Cell Census Network (U01MH117023), Alzheimers Research UK (ARUK-IRG2019A-003), European Research Council (Starting Grant 677697), EPSRC-funded UCL Centre for Doctoral Training in Medical Imaging (EP/L016478/1), and the Tiny Blue Dot Foundation. This work was also made possible by resources provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. Additional support was provided by the NIH Blueprint for Neuroscience Research (U01MH093765), part of the multi-institutional Human Connectome Project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval This retrospective study was approved by the Mass General Brigham Institutional Review Board. Informed consent was waived given the retrospective nature of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-first authors
↵** co-senior authors
Funding: This study was supported by the James S. McDonnell Foundation COVID-19 Recovery of Consciousness Consortium, the NIH Director’s Office (DP2HD101400), the NIH National Institute of Neurological Disorders and Stroke (R21NS109627, R25NS06574309, R01NS0525851, R21NS072652, R01NS070963, R01NS083534, U01NS086625, U24NS10059103, R01NS105820), NIH National Institute on Aging (R01AG070988, R56AG064027, R01AG064027, R01AG008122, R01AG016495), NIH National Institute for Biomedical Imaging and Bioengineering (P41EB015896, R01EB023281, R01EB006758, R21EB018907, R01EB019956, P41EB030006), NIH National Institute of Mental Health (R01MH123195, R01MH121885, RF1MH123195), NIH BRAIN Initiative (RF1MH123195), BRAIN Initiative Cell Census Network (U01MH117023), Alzheimer’s Research UK (ARUK-IRG2019A-003), European Research Council (Starting Grant 677697), EPSRC-funded UCL Centre for Doctoral Training in Medical Imaging (EP/L016478/1), and the Tiny Blue Dot Foundation. This work was also made possible by resources provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. Additional support was provided by the NIH Blueprint for Neuroscience Research (U01MH093765), part of the multi-institutional Human Connectome Project.
Declarations:
Ethics approval This retrospective study was approved by our Institutional Review Board.
Informed consent Informed consent was waived given the retrospective nature of the study.
Conflicts of interests BF has a financial interest in CorticoMetrics, a company whose medical pursuits focus on brain imaging and measurement technologies. BF’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.